Alaye siwaju sii ― Yoruba

Postinflammatory hyperpigmentation (PIH) jẹ iṣoro awọ ara loorekoore ti o ṣẹlẹ lẹhin iredodo awọ tabi ipalara. O le duro fun igba pipẹ, ó sì buru jùlọ ní àwọn ènìyàn tí ó ní awọ dudu (Fitzpatrick skin types III–VI). Botilẹjẹpe ó máa ń dara sí ara rẹ, èyí lè gba ìgbà díẹ̀, nítorí náà a nílò itọju to peye fún àkókò pípẹ́. Apapọ àwọn itọju oríṣìíríṣìí n ṣiṣẹ́ dára jùlọ.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.

Postinflammatory hyperpigmentation jẹ́ atẹle tí ó wọ́pọ̀ ti iredodo awọ ara. Ó maa n ní ipa díẹ̀ síi lórí àwọn ènìyàn dudu‑awọ, tí ó sì lè jẹ́ líle àti igbagbogbo. Àwọn ijinlẹ̀ fìhàn pé àwọn ọ̀ràn bíi postinflammatory hyperpigmentation wà láàrin àwọn ìdí pàtàkì tí àwọn ènìyàn tí ó ní awọ dudu ń wá ìtọ́jú. Ìtọ́jú títẹ̀sí jẹ́ pàtàkì fún ìdínkù postinflammatory hyperpigmentation, ó sì máa ń bẹ̀rẹ̀ pẹ̀lú iṣakoso iredodo àkọ́kọ́. Laini àkọ́kọ́ ti ìtọ́jú sábà máa ń jẹ́ lílo àwọn aṣọ́jú agbègbè tí ń tan awọ ara pẹ̀lú ìbòjú oorun fún ààbò. Àwọn aṣọ́jú wọ̀nyí, bíi hydroquinone, azelaic acid, kojic acid, arbutin, licorice extracts, lè ní ìmúniṣòro láti dín àwọ̀ pọ̀. Pẹ̀lú náà, retinoids, mequinol, ascorbic acid, niacinamide, N‑acetyl glucosamine, àti soy tún ń lò gẹ́gẹ́ bí àwọn aṣọ́jú tí ń ṣe àtúnṣe awọ, pẹ̀lú àwọn ìtọ́jú tuntun tí ń bọ̀. Bí ó tilẹ̀ jẹ́ pé àwọn ìtọ́jú agbègbè máa ń munadoko fún hyperpigmentation ipele‑dada, àwọn ìlànà bíi laser tàbí chemical peel lè jẹ́ dandan fún àwọn ọ̀ràn alágbára. Ó ṣe pàtàkì láti lo ìṣọ́ra pẹ̀lú àwọn ìtọ́jú wọ̀nyí kí a má bà a kúrò ní ìbànújẹ̀ àti kí a má ṣe kó postinflammatory hyperpigmentation pọ̀ sí i.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.